Tag: cannabinoid pharmaceutical R&D
AusCann raises A$33.4m via share placement
ASX-listed medical marijuana company AusCann has successfully raised A$33.4 million via a share placement to institutional and sophisticated investors from North America and Australia, including...
Featured Article
The economic forces driving manufacturing’s next cycle
Australia’s manufacturing sector entered 2026 with improving momentum, but renewed global disruption is again testing resilience across the industry.
